熱門資訊> 正文
HUT,CXAI和BDRX在市场前的输家中
2024-04-02 20:37
- Losers: Acorda Therapeutics (ACOR) -76% as it files for Chapter 11 bankruptcy.
- Gritstone Bio (GRTS) -43% on prices $32.5M equity offering.
- Verve Therapeutics (VERV) -36% after pausing trial enrollments for lead asset.
- Canoo (GOEV) -29% reports mixed Q4 results.
- PVH Corp (PVH) -23% after Q4 earnings release.
- Avalo Therapeutics (AVTX) -20% appoints Biotech leaders to board of directors.
- Pioneer Power Solutions (PPSI) -19% after Q4 earnings release.
- Petros Pharmaceuticals (PTPI) -19%.
- Imuno (IMNN) -13%.
- CXApp (CXAI) -14%.
- Terran Orbital Corp (LLAP) -12% after Q4 earnings release.
- Xilio Therapeutics (XLO) -12% reports Q4 results.
- AST SpaceMobile (ASTS) -11% after FY earnings release.
- Humana (HUM) -10%.
- Biodexa Pharmaceuticals Plc (BDRX) -10%.
- Hut 8 Corp (HUT) -9%.
- iBio (IBIO) -9%.
- Allego NV (ALLG) -9% to postpone fourth quarter and full year 2023 financial results conference call.
- Ocugen (OCGN) -8% provides business update with certain financials for the year ending 2023.
- Petco Health and Wellness Co (WOOF) -8% after double downgrade from BofA.
- Griid Infrastructure (OTCPK:GRDI) -7%.
- Lytus Technologies Holdings PTV Ltd (LYT) -8%.
- Cipher Mining (CIFR) -7% bitcoin production slips 5% M/M in March.
- Microstrategy (MSTR) -7%.
- Argo Blockchain Plc (ARBK) -7%.
More on Pre-market losers & stocks.
- Hut 8 Mining Corp. (HUT) Q4 2023 Earnings Call Transcript
- From Bull To Bear: Recent Events Drove Me To Exit My Position In HUT 8
- Hut 8 Post-Merger Comprehensive Thesis: JCapital Research Might Be Right
- Hut 8 stock jumps 14% after six-month results turn a profit
- Hut 8 GAAP EPS of $0.11, revenue of $60.61M
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。